AQP4 and neuromyelitis optica: It is important to note that they may lead to the discovery of effective therapies as reported with the humanized IL6-receptor antibody, satralizumab, in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD)2 and serve as prognostic biomarkers.